Appendix 1. Chart Abstraction Form
Form Approved
CDC ID:_____
OMB No. 0920-XXXX
Exp. Date XX/XX/XXXX
Patient Name: ________________________________________________________
CDC ID#:____________________________________________________________
Hospital #1: _________________________________________________________
MRN#: ___________________________________________________
Hospital #2 (if transferred): _____________________________________________
MRN#: ___________________________________________________
Street Address: _______________________________________________________
City: ________________________ State: _______ Zip: ____________
Country:_________________
Telephone number: ______________________
Alt Telephone number:______________________
Public reporting burden of this collection of information is estimated to average XX minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-XXXX)
Name of person completing form:_______________________________________________ |
||||||||||||
Demographic Information |
||||||||||||
Age: ________ DOB___ __/ __ __ / __ __ __ __ |
|
|||||||||||
Sex: Male Female |
|
|||||||||||
What is your race? (Check all that apply.): American Indian or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islander White
|
||||||||||||
Are you Hispanic or Latino?: Yes No |
|
|||||||||||
Work (describe): |
|
|||||||||||
Timeline and Outcome |
|
|||||||||||
Date of prodrome (includes GI symptom) onset: ____/____/_________ |
No prodrome |
|||||||||||
Date of neuro illness onset: ____/____/_________ |
|
|||||||||||
Date of first hospital admission: ____/____/_________ |
|
|||||||||||
Initial or admitting diagnosis: |
|
|||||||||||
Outcome of illness: Died (Date (dd/mmm/yyyy):_________________) Discharged to chronic care or rehabilitation facility Discharged to home (Date:_________________) Still hospitalized |
(Date:_________________) |
|||||||||||
Prodrome Illness Symptoms |
|
|||||||||||
Diarrhea Yes No Unk Vomiting Yes No Unk Fever Yes No Unk Cough Yes No Unk Sore Throat Yes No Unk Joint pains/aches Yes No Unk |
Bloody stool Yes No Unk Rash Yes No Unk Headache Yes No Unk Abdominal Pain Yes No Unk Other__________________________ |
|||||||||||
Duration of prodromal symptoms: ___________ days |
|
|||||||||||
Location of patient in 7 days before prodromal symptoms: |
|
|||||||||||
Past Medical and Neurological History |
|
|||||||||||
Past Medical and Neurological History (include EtOH, tobacco, drug use): |
|
|||||||||||
Exposure History |
|
|||||||||||
Travel History (include all places visited in prior 30 days—include dates of travel):
|
|
|||||||||||
Describe any agricultural or pesticide exposure in past 6 weeks: |
|
|||||||||||
Any upper respiratory infection in the last 6 weeks? Yes No Unk If yes, |
What date of onset?: ____/____/_________ |
|||||||||||
Any gastrointestinal infection in the last 6 weeks? Yes No Unk If yes, |
What date of onset?: ____/____/_________ |
|||||||||||
Any vaccinations received in the last 6 weeks? Yes No Unk
|
If yes, date of receipt: __ / __/ _____ If yes, vaccine(s)_administered________________________________ |
|||||||||||
Ill household contacts in the past 6 weeks? Yes No Unk If yes, |
Nature of illness: _____________________________________________________ |
|||||||||||
Toxic/Chemical Exposures |
|
|||||||||||
1. Did patient recall taking any herbal or folk remedies during 2 weeks prior to illness onset? |
Yes |
No |
Unknown |
|
||||||||
If YES, |
Remedy 1: __________________________________ |
|
||||||||||
Remedy 2: __________________________________ |
|
|||||||||||
3. Did patient recall eating any wild picked plants (like. buckthorn or Karwinskia Humboldt pictured below) during 2 weeksprior to illness onset? |
Yes |
No |
Unknown |
|
||||||||
If YES, |
Plant 1: __________________________________ |
|
||||||||||
Plant 2: __________________________________ |
|
|||||||||||
Neuro Symptoms |
|
|||||||||||
Initial neurological signs and symptoms (describe): |
|
|
||||||||||
Onset of weakness within first week of neuro illness? |
Yes |
No |
Unknown |
|||||||||
Concurrent symptoms: |
Fever |
Headache |
Meningismus (nuchal rigidity, photo/phonophobia) |
|||||||||
Altered mental status |
Nausea/vomiting |
Muscle pain/myalgia |
Other |
|||||||||
Specify if other: __________________________________________________________________________________________ |
Distribution of weakness at first onset (e.g. first noted weakness) |
Symmetric |
Asymmetric |
Unknown |
||||||||||
Check all that apply: |
Right UE |
Left UE |
Right LE |
Left LE |
|||||||||
|
Prox |
Dist |
Prox |
Dist |
Prox |
Dist |
Prox |
Dist |
|||||
Neck Flexors/Extens. |
Respiratory muscles |
Quadriplegia/whole body paralysis |
Facial muscles |
||||||||||
Describe weakness distribution: __________________________________________________________________________ |
|||||||||||||
Nature of weakness onset: |
|||||||||||||
Ascending |
Descending |
Acute/whole limb |
Unknown |
||||||||||
Approximate time interval to maximal weakness: ________________________ |
Distribution of weakness at maximal weakness |
Symmetric |
Asymmetric |
Unknown |
|
||||||||||||||||||||
Check all that apply: |
Right UE |
Left UE |
Right LE |
Left LE |
|
|||||||||||||||||||
|
Prox |
Dist |
Prox |
Dist |
Prox |
Dist |
Prox |
Dist |
|
|||||||||||||||
Neck Flexors/Extens. |
Respiratory muscles |
Quadriplegia/whole body paralysis |
Facial muscles |
|
||||||||||||||||||||
Describe weakness distribution at maximum: ___________________________________________________________________ |
|
|||||||||||||||||||||||
Approximate date of maximal weakness: ____/____/_______________ |
|
|||||||||||||||||||||||
Reflexes in affected body parts at time of maximal weakness: |
Areflexic |
Hyporeflexic |
Reflexes normal |
|
||||||||||||||||||||
Hyperreflexic/spastic |
Reflexes not tested |
Unknown |
|
|
|
|||||||||||||||||||
Tone in affected body parts at time of maximal weakness: |
Flaccid |
Hypotonic |
Tone normal |
|
||||||||||||||||||||
Hypertonic/spastic |
Tone not tested |
Unknown |
|
|
|
|||||||||||||||||||
Sensory abnormalities present? |
Yes |
No |
Unknown |
|
||||||||||||||||||||
Date of sensory symptom onset: _____/_____/____________ |
|
|||||||||||||||||||||||
Description of sensory abnormalities: __________________________________________________________________________ type _____________________________________ |
|
|||||||||||||||||||||||
Pain present? |
Yes |
No |
Unknown |
|
||||||||||||||||||||
Date of pain onset: ____/____/_________________ |
|
|||||||||||||||||||||||
Description/location of pain: _________________________________________________________________________ |
|
|||||||||||||||||||||||
Prominent dyspnea/shortness of breath present? |
Yes |
No |
Unknown |
|
||||||||||||||||||||
Approximate date of dyspnnea onset: ____/____/__________ |
|
|
|
|
||||||||||||||||||||
Patient ever intubated? |
Yes |
No |
Unknown |
If yes, date of intubation: |
||||||||||||||||||||
Date of extubation: |
Tracheostomy required? |
Yes |
No |
Unknown |
||||||||||||||||||||
Bowel/Bladder involvement present? |
Yes |
No |
Unknown |
|||||||||||||||||||||
Description of bowel/bladder involvement: _______________________________________________________________ |
||||||||||||||||||||||||
Date of bowel/bladder involvement: ____/____/__________________ |
Dysarthria and/or dysphagia present? |
Yes |
No |
Unknown |
|||||
Date of dysarthria/dysphagia: ____/____/___________ |
||||||||
Description of dysarthria/dysphagia: ______________________________________________________________________________ |
||||||||
15. Any other cranial nerve abnormalities present? |
Yes |
No |
Unknown |
|||||
If yes, specify cranial nerve abnormality, as specifically as possible: |
||||||||
Date of onset of CN abnormality: ____/____/____________ |
Date of resolution of CN abnormality: ____/____/____________ |
|||||||
Ataxia present? Yes No Unknown |
||||||||
If yes, date ataxia noted / recorded: ___/___/________ |
|
|||||||
|
||||||||
Does the Neurology Consult Note attribute neurologic symptoms to a definitive diagnosis other than Guillain-Barre Syndrome? Yes No If yes, what was the rendered diagnosis: ___________________________________________ |
||||||||
Hospital Course |
||||||||
Please list nosocomial complications (if any): |
||||||||
|
||||||||
Laboratory Testing |
|
|
||||||
Serum Potassium ____________ on admission ____________ most abnormal Serum Calcium ____________ on admission ____________ most abnormal |
|
|
|
|||||
Cerebrospinal fluid |
|
|
||||||
Did the patient have any lumbar punctures (LP) performed within 30 days of onset of weakness? Yes No Unknown |
|
|
||||||
Date CSF 1: __/__/____ WBC _____/mm3 RBC_____/mm3 Protein_____ mg/dL Glucose_____ mg/dL |
|
|
||||||
WBC differential: Neutrophils_____% Lymphocytes______% Monocytes______% Eosinophils_____% |
|
|
||||||
Date CSF 2: __/__/____ WBC _____/mm3 RBC_____/mm3 Protein_____ mg/dL Glucose_____ mg/dL |
|
|
||||||
WBC differential: Neutrophils_____% Lymphocytes______% Monocytes______% Eosinophils_____% |
|
|
||||||
12. CSF Gram’s Stain: |
Record result:__________________________________________ |
|
|
|||||
13. CSF VRDL: |
14. CSF Cryptococcal Antigen: |
|
|
|||||
18. CSF Oligoclonal Bands: |
19. IgG Index: |
|
|
|||||
20. IgG Synthesis Rate: |
21. Myelin Basic Protein: |
|
|
Neurodiagnostics: Please indicate whether the following tests were performed. Record all results on accompanying worksheet. |
|
|||||||||
1. Head computed tomography |
2. Spinal computed tomography |
|
||||||||
3. Brain magnetic resonance imaging |
4. Spinal magnetic resonance imaging |
|
||||||||
5. Electromyography/nerve conduction studies |
6. Pulmonary fluoroscopic studies |
|
||||||||
|
|
|
|
|
||||||
Please indicate whether any of the following treatments or procedures were rendered during the course of illness: |
||||||||||
1. Intravenous Immune Globulin (IVIG) |
Date started: ____/____/_____ |
Date stopped: ____/____/_______ |
|
|||||||
2. Plasmapheresis/plasma exchange |
Date started: ____/____/_____ |
Date stopped: ____/____/_______ |
|
|||||||
3. Alpha-interferon |
Date started: ____/____/_____ |
Date stopped: ____/____/_______ |
|
|||||||
4. Corticosteroids |
Date started: ____/____/_____ |
Date stopped: ____/____/_______ |
|
|||||||
If yes, dosage used: __________________________________________________________________ |
|
|||||||||
5. Other immunomodulating agent (Imuran, etc.) |
Date started: ____/____/_____ |
Date stopped: ____/____/_______ |
|
|||||||
If yes, specify: _________________________________________________ |
|
|||||||||
7. Muscle biopsy |
If yes, date obtained: ____/____/______________ |
|
|
|||||||
If yes, specify site of biopsy: _______________________________________________________________________ |
|
|||||||||
If yes, narrative of result: ________________________________________________________________________________________ |
|
|||||||||
_______________________________________________________________________________________________________________ |
|
|
Lab results: Culture results |
|
||||||||||||||
|
If any bacterial, viral or fungal culture results were obtained, please note the following results |
|
||||||||||||||
|
|
|
Culture type |
Result |
|
|
||||||||||
Specimen type* |
Date |
(Check one) |
(Check one) |
If positive: |
|
|||||||||||
|
|
|
Bacterial |
Viral |
Fungal |
No growth |
Positive |
Organism 1 |
Organism 2 |
Organism 3 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
*Specimen type: Blood, bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), nasopharyngeal swab/aspirate, pericardial fluid, peritoneal fluid, pleural fluid, sputum, synovial fluid, tissue (specify site), throat/oropharyngeal swab, stool or urine |
|
||||||||||||||
Diagnostic Tests for Other Infectious Diseases (include Antibody tests/serology, antigen detection, PCR and special stains) |
||||||||||||||||
Specimen type* |
Date |
Test performed |
Results |
Interpretation |
Laboratory |
|||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|||||||||||
|
||||||||||||||||
*Specimen type: Blood, bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), nasopharyngeal swab/aspirate, pericardial fluid, peritoneal fluid, pleural fluid, acute serum, convalescent serum, paired sera, sputum, synovial fluid, tissue (specify site), throat/oropharyngeal swab, stool or urine |
Please attach results of all neurodiagnostics (include detailed EMG results if available):
FINAL BRIGHTON CASE DEFINITION CLASSIFICATION: (See Appendix
Guillain-Barre Syndrome
Level I
Level 2
Level 3
Level 4
Level 5
Fisher Syndrome:
Level I
Level 2
Level 3
Level 4
Level 5
APPENDIX I: BRIGHTON CASE DEFINITION CRITERIA
Guillain-Barré Syndrome
Level I (requires ALL criteria)
Bilateral AND flaccid weakness of the limbs
Decreased or absent deep tendon reflexes in weak limbs
Monophasic illness pattern AND interval between onset and nadir of illness between 12 hours and 28 days AND subsequent clinical plateau
Electrophysiologic findings consistent with GBS
Cytoalbuminologic dissociation (i.e., elevation of CSF protein level above laboratory normal value AND CSF total white cell count <50 cells / mm3
Absence of an identified alternative diagnosis for weakness
Level 2
Criteria 1, 2, and 3 for Level 1 fulfilled
AND
CSF total white cell count <50 cells/mm3 (with or without CSF protein elevation above laboratory normal value)
OR
If CSF not collected or results not available, electrophysiologic studies consistent with GBS
Absence of identified alternative diagnosis for weakness
Level 3
Criteria 1, 2, and 3 for Level 1 fulfilled
Absence of identified alternative diagnosis for weakness
Level 4
Reported event of GBS, with insufficient evidence to meet case definition
Level 5
Not a case of GBS
Fisher Syndrome
Level 1 (Requires ALL Criteria)
Bilateral ophthalmoparesis AND bilateral reduced or absent tendon reflexes, AND ataxia
Absence of limb weakness
Monophasic illness pattern AND interval between onset and nadir of weakness between 12 hours and 28 days AND subsequent clinical plateau
Cytoalbuminologic dissociation (i.e., elevation of cerebrospinal protein above the laboratory normal AND total CSF white cell count <50 cells/mm3)
Nerve conduction studies are normal, OR indicate involvement of sensory nerves only
No alteration in consciousness or corticospinal tract signs
Absence of an identified alternative diagnosis
Level 2
Criteria 1, 2, and 3 for Level 1 fulfilled
AND
Cerebrospinal fluid (CSF) with a total white cell count <50 cells/mm3 (with or without CSF protein elevation above laboratory normal value)
OR
Nerve conduction studies are normal, OR indicate involvement of sensory nerves only
No alteration in consciousness or corticospinal tract signs
Absence of an identified alternative diagnosis
Level 3
Criteria 1, 2, 3, 6, and 7 for Level 1 fulfilled
Levels 4 and 5 as for GBS
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Centers for Disease Control & Prevention |
File Modified | 0000-00-00 |
File Created | 2022-10-10 |